C
Carlo Salvarani
Researcher at University of Modena and Reggio Emilia
Publications - 854
Citations - 37620
Carlo Salvarani is an academic researcher from University of Modena and Reggio Emilia. The author has contributed to research in topics: Medicine & Giant cell arteritis. The author has an hindex of 88, co-authored 730 publications receiving 31699 citations. Previous affiliations of Carlo Salvarani include Queen Mary University of London & University of Parma.
Papers
More filters
Journal ArticleDOI
Polymyalgia rheumatica and giant-cell arteritis.
Journal ArticleDOI
EULAR Recommendations for the management of primary small and medium vessel vasculitis
Chetan Mukhtyar,Loïc Guillevin,Maria C. Cid,Bhaskar Dasgupta,K de Groot,Wolfgang L. Gross,Thomas H. Hauser,B Hellmich,David Jayne,Cees G. M. Kallenberg,Peter A. Merkel,Heiner Raspe,Carlo Salvarani,Dgi Scott,Coen A. Stegeman,Richard A. Watts,Kerstin Westman,James Witter,Halil Yazici,Raashid Luqmani +19 more
TL;DR: On the basis of evidence and expert consensus, recommendations have been made for the evaluation, investigation, treatment and monitoring of patients with small and medium vessel vasculitis for use in everyday clinical practice.
Journal ArticleDOI
Trial of Tocilizumab in Giant-Cell Arteritis.
John H. Stone,Katie Tuckwell,Sophie Dimonaco,Micki Klearman,Martin Aringer,Daniel Engelbert Blockmans,Elisabeth Brouwer,Maria C. Cid,Bhaskar Dasgupta,Juergen Rech,Carlo Salvarani,Georg Schett,Hendrik Schulze-Koops,Robert Spiera,Sebastian Unizony,Neil Collinson +15 more
TL;DR: Tocilizumab, received weekly or every other week, combined with a 26‐week prednisone taper was superior to either 26‐ week or 52‐weekprednisone tapering plus placebo with regard to sustained glucocorticoid‐free remission in patients with giant‐cell arteritis.
Journal ArticleDOI
The International Criteria for Behçet's Disease (ICBD): A collaborative study of 27 countries on the sensitivity and specificity of the new criteria
Fereydoun Davatchi,Samir H. Assaad-Khalil,Kenneth T. Calamia,J. E. Crook,Bahar Sadeghi-Abdollahi,Michael Schirmer,T. Tzellos,Christos C. Zouboulis,M. Akhlagi,A. Al-Dalaan,Z. S. Alekberova,A. A. Ali,A. Altenburg,E. Arromdee,M. Baltaci,M. Bastos,S. Benamour,I. Ben Ghorbel,Ayşe Boyvat,L. Carvalho,WenChieh Chen,E. Ben-Chetrit,Cheyda Chams-Davatchi,J. A. Correia,J. Crespo,Carlos Tadeu dos Santos Dias,Y. Dong,F. Paixão-Duarte,K. Elmuntaser,A. V. Elonakov,J. Graña Gil,Ali Akbar Haghdoost,R. M. Hayani,Habib Houman,A. R. Isayeva,Ahmadreza Jamshidi,Phaedon G. Kaklamanis,Ashok Kumar,Athanassios Kyrgidis,Wafa Madanat,Abdolhadi Nadji,Kenichi Namba,Shigeaki Ohno,I. Olivieri,J. Vaz Patto,Nicolò Pipitone,M. V. De Queiroz,F. Ramos,C. Resende,C. M. Rosa,Carlo Salvarani,M. J. Serra,Farhad Shahram,Hormoz Shams,Khalifa E. Sharquie,M. Sliti-Khanfir,T. Tribolet De Abreu,C. Vasconcelos,Joana Vedes,Bertrand Wechsler,Y. K. Cheng,Zilong Zhang,N. Ziaei +62 more
TL;DR: Behçet's disease (BD) is a chronic, relapsing, inflammatory vascular disease with no pathognomonic test.
Journal ArticleDOI
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
Giovanni Guaraldi,Marianna Meschiari,Alessandro Cozzi-Lepri,Jovana Milic,Roberto Tonelli,Marianna Menozzi,Erica Franceschini,Gianluca Cuomo,Gabriella Orlando,Vanni Borghi,Antonella Santoro,Margherita Di Gaetano,Cinzia Puzzolante,Federica Carli,Andrea Bedini,Luca Corradi,Riccardo Fantini,Ivana Castaniere,Luca Tabbì,Massimo Girardis,Sara K. Tedeschi,Maddalena Giannella,Michele Bartoletti,Renato Pascale,Giovanni Dolci,Lucio Brugioni,Antonello Pietrangelo,Andrea Cossarizza,Federico Pea,Enrico Clini,Carlo Salvarani,Marco Massari,Pierluigi Viale,Cristina Mussini +33 more
TL;DR: Assessment of the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment found it to be associated with a reduced risk.